pramipexole has been researched along with rosiglitazone in 3 studies
| Studies (pramipexole) | Trials (pramipexole) | Recent Studies (post-2010) (pramipexole) | Studies (rosiglitazone) | Trials (rosiglitazone) | Recent Studies (post-2010) (rosiglitazone) |
|---|---|---|---|---|---|
| 1,103 | 219 | 517 | 4,749 | 556 | 1,818 |
| Protein | Taxonomy | pramipexole (IC50) | rosiglitazone (IC50) |
|---|---|---|---|
| CDGSH iron-sulfur domain-containing protein 1 | Rattus norvegicus (Norway rat) | 1.1 | |
| Bile salt export pump | Homo sapiens (human) | 4.5853 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 4.069 | |
| Peroxisome proliferator-activated receptor alpha | Mus musculus (house mouse) | 0.08 | |
| Thromboxane-A synthase | Homo sapiens (human) | 3.56 | |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | 0.832 | |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | 0.2481 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.038 | |
| ATP-binding cassette sub-family C member 8 | Homo sapiens (human) | 0.048 | |
| ATP-sensitive inward rectifier potassium channel 11 | Homo sapiens (human) | 0.048 | |
| Sodium/bile acid cotransporter | Homo sapiens (human) | 5.1 | |
| CDGSH iron-sulfur domain-containing protein 2 | Homo sapiens (human) | 2.29 | |
| CDGSH iron-sulfur domain-containing protein 1 | Homo sapiens (human) | 0.731 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Buerger, E; Ferrari-Toninelli, G; Maccarinelli, G; Memo, M; Uberti, D | 1 |
1 review(s) available for pramipexole and rosiglitazone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for pramipexole and rosiglitazone
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole.
Topics: Antioxidants; Apoptosis; Benzothiazoles; Cell Culture Techniques; Cell Survival; Dopamine Antagonists; Drug Delivery Systems; Humans; Hydrogen Peroxide; Mitochondria; Neurons; Neuroprotective Agents; Oxidative Stress; Pramipexole; Reactive Oxygen Species; Rosiglitazone; Thiazolidinediones; Tumor Cells, Cultured | 2010 |